Novel agent ENT-03 demonstrates promising metabolic improvements and safety in first-in-human study, setting stage for further development in …
Novel agent ENT-03 demonstrates promising metabolic improvements and safety in first-in-human study, setting stage for further development in …
CEO Lamballe highlights strategic advances, upcoming trial readouts, and expansion of microbiome ecosystem therapies pipeline.
Phase 3 trial data show promising metabolic improvements and durable weight reduction, expanding potential treatment options for millions.
Sustained-release axitinib hydrogel shows promising efficacy and safety in wet age-related macular degeneration and diabetic retinopathy, setting foundation …
First biologic approved for this rare autoimmune blistering skin disease; pivotal trial data drive swift Priority Review.
Commercial partnership targets scalability, 24/7 PET imaging product access, and future expansion for next-gen cancer diagnostics.
Mid-stage data reveal safety and efficacy signals supporting potential shift in frontline treatment for higher-risk MDS patients.
Once-monthly subcutaneous treatment offers new option for preventing hereditary angioedema attacks across all patient types from therapy initiation.
Combination of ZYNLONTA® and glofitamab (COLUMVI®) shows durable complete responses and manageable safety profile in Phase 1b study.
Early Access Program data supports robust efficacy and safety, reinforcing results from the pivotal ARES trial and strengthening …
Already a subscriber? Log in